{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Insmed, Inc. Hits New 52-Week High of $163.22, Up 170% Yearly
Insmed, Inc. has achieved a new 52-week high of USD 163.22, reflecting a significant increase in its stock price over the past year. With a market capitalization of approximately USD 31 billion, the company shows strong market momentum despite ongoing financial challenges, including a low return on equity.
Insmed, Inc. Hits New 52-Week High of $162.44, Up 171% Year-Over-Year
Insmed, Inc. has achieved a new 52-week high, reflecting a significant increase in its stock performance over the past year. With a market capitalization of approximately USD 31 billion, the company maintains a high price-to-book ratio and a negative debt-to-equity ratio, indicating a focus on growth despite current losses.
Insmed, Inc. Hits New 52-Week High of $160.62, Up 164% Yearly
Insmed, Inc. has achieved a new 52-week high of USD 160.62, reflecting a significant performance increase of 164.24% over the past year. With a market capitalization of USD 31 billion, the company maintains a high price-to-book ratio and a unique financial structure, despite ongoing losses.
Insmed, Inc. Hits New 52-Week High of $158.19, Up 162%
Insmed, Inc. has achieved a new 52-week high of USD 158.19, reflecting a significant increase in its stock price over the past year. With a market capitalization of approximately USD 31 billion, the company has garnered attention despite being loss-making and not offering dividends. Its financial structure includes a notable price-to-book ratio and a negative debt-to-equity ratio.
Insmed, Inc. Hits Day High with Strong 5.09% Intraday Surge
Insmed, Inc. has seen a significant rise in its stock performance, reaching an intraday high and outperforming the S&P 500 over the past month and year. However, the company faces financial challenges, including negative operating cash flow and a high price-to-book ratio, indicating potential underlying pressures.
Is Insmed, Inc. technically bullish or bearish?
As of July 21, 2025, Insmed, Inc. shows a bullish trend with strong MACD indicators, despite some bearish signals from the RSI, and has significantly outperformed the S&P 500 with a year-to-date return of 111.27%.
Is Insmed, Inc. overvalued or undervalued?
As of February 22, 2019, Insmed, Inc. is considered risky and overvalued, with alarming negative financial ratios and inefficiencies, despite outperforming the S&P 500 year-to-date.
Is Insmed, Inc. overvalued or undervalued?
As of February 22, 2019, Insmed, Inc. is considered risky and overvalued due to poor financial metrics, including a Price to Book Value of 135.23 and a negative ROCE of -483.80%, despite a recent stock performance of 56.11% that outpaces the S&P 500.
Is Insmed, Inc. technically bullish or bearish?
As of June 20, 2025, Insmed, Inc. shows a strong bullish trend supported by positive MACD and Bollinger Bands, despite some caution from the monthly RSI and KST indicators.
Who are in the management team of Insmed, Inc.?
As of March 2022, Insmed, Inc.'s management team includes William Lewis as Chairman, President, and CEO, and David Brennan as Lead Independent Director, along with independent directors Carol Schafer, Alfred Altomari, Elizabeth Anderson, and Clarissa Desjardins.
What does Insmed, Inc. do?
Insmed, Inc. is a global biopharmaceutical company focused on developing treatments for rare diseases, with a market cap of approximately $19 billion. As of March 2025, it reported net sales of $93 million and a net loss of $257 million.
How big is Insmed, Inc.?
As of Jun 18, Insmed, Inc. has a market capitalization of $19.05 billion, with net sales of $381.02 million and a net profit loss of $1.01 billion over the latest four quarters. Shareholder's funds are $285.38 million, and total assets amount to $2.03 billion.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
